Acquisitions, Mergers & PartnershipsBiomaterialsBioprinting

Aspect Biosystems and JDRF partner to treat type 1 diabetes

Developing a bioengineered tissue therapeutic - providing insulin independence

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Aspect Biosystems, a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is set to partner with JDRF, a leading global type 1 diabetes (T1D) research and advocacy organization.

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since its inception. JDRF collaborates with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D.

lab-on-a-printer
Aspect Biosystems RX1 bioprinter

Aspect Biosystems partnership with JDRF supports Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression. In addition to funding, JDRF is also contributing strategic support through its deep expertise and vast network in the diabetes field.

Aspect is leveraging its proprietary bioprinting technology, therapeutic cells, and materials science to create a pipeline of cell-based tissue therapeutics that replace or repair damaged organ functions. These therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation to treat diseases such as type 1 diabetes.

“For more than 20 years, JDRF has been a leader in cell-based tissue therapy research for type 1 diabetes,” said Esther Latres, Assistant Vice President of Research at JDRF. “This funding partnership with Aspect Biosystems will support and continue scientific advancements in the field and undeniably take us closer to finding a cure.”

“Together with JDRF, we are aligned on the mission to develop a curative therapy for the millions of patients around the world who are affected by type 1 diabetes,” said Tamer Mohamed, CEO at Aspect Biosystems. “This partnership will help advance our cutting-edge pancreatic tissue program and bring us a step closer to human trials.”

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!